We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.29B
AUM Growth
+$370M
Cap. Flow
+$32.1M
Cap. Flow %
2.48%
Top 10 Hldgs %
19.69%
Holding
198
New
29
Increased
74
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$20.7M
2
AVTR icon
Avantor
AVTR
+$14.9M
3
TGTX icon
TG Therapeutics
TGTX
+$13.5M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$11.4M
5
TXG icon
10x Genomics
TXG
+$10.3M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.9M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M
4
PEN icon
Penumbra
PEN
+$10.1M
5
TWST icon
Twist Bioscience
TWST
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.02%
2 Technology 12.16%
3 Consumer Discretionary 8.78%
4 Industrials 6.66%
5 Financials 5.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
1
TG Therapeutics
TGTX
$7.07B
$32.7M 2.52%
628,172
+398,720
+174% +$13.5M
BBIO icon
2
BridgeBio Pharma
BBIO
$15.7B
$29.3M 2.26%
411,771
+118,789
+41% +$5.73M
TWST icon
3
Twist Bioscience
TWST
$6.29B
$25.3M 1.95%
178,875
-90,645
-34% -$10.1M
TDOC icon
4
Teladoc Health
TDOC
$1.21B
$25.2M 1.95%
126,104
+32,704
+35% +$6.65M
RGEN icon
5
Repligen
RGEN
$8.3B
$25M 1.93%
130,491
+290
+0.2% +$52.8K
ARGX icon
6
argenx
ARGX
$52B
$24.5M 1.89%
83,328
-77
-0.1% -$21.2K
IOVA icon
7
Iovance Biotherapeutics
IOVA
$1.93B
$23.6M 1.82%
507,651
+837
+0.2% +$33.2K
NVCR icon
8
NovoCure
NVCR
$1.78B
$23.4M 1.81%
135,336
-64,277
-32% -$8.8M
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$23.2M 1.79%
270,362
+18,416
+7% +$1.56M
KRNT icon
10
Kornit Digital
KRNT
$734M
$22.8M 1.76%
256,334
-13,820
-5% -$1.06M
NEO icon
11
NeoGenomics
NEO
$2.04B
$22.7M 1.75%
420,807
+717
+0.2% +$32.4K
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$22.4M 1.73%
183,676
+319
+0.2% +$34.9K
CZR icon
13
Caesars Entertainment
CZR
$6.06B
$22M 1.7%
295,852
+3,408
+1% +$214K
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
$21.3M 1.64%
+276,633
New +$20.7M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$20.9M 1.61%
285,046
+20,690
+8% +$1.54M
MPWR icon
16
Monolithic Power Systems
MPWR
$66B
$20.3M 1.57%
55,526
+247
+0.4% +$79.2K
EXAS
17
DELISTED
Exact Sciences
EXAS
$20.1M 1.55%
151,746
+234
+0.2% +$28.3K
INSP icon
18
Inspire Medical Systems
INSP
$1.5B
$19.8M 1.53%
105,095
-1,018
-1% -$166K
SDGR icon
19
Schrodinger
SDGR
$1.14B
$19.7M 1.52%
248,806
+12,983
+6% +$816K
GH icon
20
Guardant Health
GH
$21.3B
$19.6M 1.51%
152,048
+13,948
+10% +$1.6M
OSH
21
DELISTED
Oak Street Health, Inc.
OSH
$18.6M 1.43%
303,407
+46,492
+18% +$2.44M
LSCC icon
22
Lattice Semiconductor
LSCC
$18B
$18M 1.39%
392,706
-42,729
-10% -$1.65M
AXSM icon
23
Axsome Therapeutics
AXSM
$10.9B
$16.9M 1.31%
207,452
+19,696
+10% +$1.47M
AVTR icon
24
Avantor
AVTR
$9.25B
$16.3M 1.26%
+579,037
New +$14.9M
CELL
25
DELISTED
PhenomeX Inc. Common Stock
CELL
$15.9M 1.23%
177,724
+135,440
+320% +$11.4M
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Nicholas Investment Partners held 198 positions worth $1.29B, up 40% from $925M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Nicholas Investment Partners's Q4 2020 filing shows 29 new, 74 increased, 24 reduced and 25 closed positions. Its largest new stake was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M. The largest sale was Immunomedics Inc, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Nicholas Investment Partners's largest Q4 2020 buy was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M.
  • Nicholas Investment Partners added most to TG Therapeutics in Q4 2020, an estimated $13.5M increase.
  • Nicholas Investment Partners's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $10.1M.
  • Nicholas Investment Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $20.9M.
  • Nicholas Investment Partners's ten largest holdings make up 20% of its $1.29B portfolio in Q4 2020.
  • Nicholas Investment Partners opened 29 new positions and closed 25 in Q4 2020.
  • Nicholas Investment Partners's portfolio value rose 40% quarter-over-quarter to $1.29B.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.